Bioventix Plc · LSE:BVXP
Bioventix — Investor Presentation (March 2023)
16 slides from Bioventix's investor presentation, Mar 27, 2023
Slide 1: Bioventix plc
04 Bioventix Bioventix plc 27 March 2023
Slide 2: Bioventix plc
1 Bioventix plc 27 March 2023 Bioventix
Slide 3: Antibodies and Blood Testing
2 Antibodies and Blood Testing ▪Bioventix creates and manufactures sheep monoclonal antibodies (SMAs). Customers incorporate these antibodies in reagent packs for use on automated blood-testing machines antigen antibody ▪Superior antibodies can facilitate improved tests ▪Bioventix sells liquid “phys
Slide 4: Diagnostic Applications for SMAs
3 Diagnostic Applications for SMAs Vitamin D Thyroid function Fertility Chest pain; heart attack Drug testing (25-OH vitamin D) (thyroxine, T3) (testo, estrogens) (troponin) (THC) ▪Bioventix has a portfolio of ~20 antibodies that are sold globally to in vitro diagnostics (IVD) companies ▪Most have b
Slide 5: Antibodies and Business Dynamics
4 Antibodies and Business Dynamics ▪Projects can be internally driven or sponsored by customers +1 year Prototype test Old test 2-4 years ▪Bioventix takes about 1 year to create new antibodies = 3-5 years total ▪Even for established diagnostics, customers take 2-4 years to prototype tests, conduct f
Slide 6: Key Year End Financials
5 Key Year End Financials £ (‘000) year to ½ year to ½ year to finnCap 30.6.22 30.12.21 30.12.22 forecast 2022/23 Sales 11,720 4,730 5,900 12,800 (+25%) P/(L) before tax 9,280 3,560 4,520 10,200 (+27%) (adjusted) P/(L) after tax 7,670 2,990 3,730 8,000 (+25%) (adjusted) Period-end cash 6,130 5,051 5
Slide 7: Bioventix
6 ▪Note: portfolio slide for the previous year 2021/22 Bioventix
Slide 8: Sales Commentary for the Period
7 Sales Commentary for the Period ▪ Physical product sales performed well • Some revenue streams are naturally spasmodic • Sales to China were strong ▪ Vitamin D and core antibody sales were in line with expectation ▪ Troponin sales have continued to increase as the use of high sensitivity tests tha
Slide 9: Longer Term Pipeline Development
8 Longer Term Pipeline Development high Amyloid (Pre-Diagnostics) Tau (Alzheimers, own-risk) ← Increasing potential value Secretoneurin (CardiNor) medium Low Industrial biomonitoring Pyrene biomonitoring (benzene, isocyanates) Low Medium high Increasing probability of success → ▪There has been a sig
Slide 10: Pipeline Development Commentary
9 Pipeline Development Commentary ▪ Secretoneurin (CardiNor/cardiac): there has been no significant progress since October 2022 - data from recent patient sample studies does show a link with heart disease read-outs. The next step for CardiNor will be to define the potential utility of secretoneurin
Slide 11: Bioventix Strategy
10 Bioventix Strategy ▪ Seek novel clinical diagnostic biomarkers that suit our antibody technology and identify partner collaborator labs ▪ Continue to focus on antibody technology development • Identify antibody creation and production technologies that are compatible with existing core SMA techno
Slide 12: Bioventix Lab, Farnham
11 Bioventix Lab, Farnham ▪ Technology development ▪ Purification and assay ▪ Cell culture ▪ Bioreactor production ▪Supply chain issues experienced in recent years have eased ▪Inflationary pressures have resulted in price increases from some raw material suppliers Bioventix
Slide 13: Bioventix Directors
12 Bioventix Directors ▪Peter Harrison, CEO ▪Ian Nicholson, Chairman ▪>30 years experience of ▪>30 years experience of antibody technology at commercial development within Celltech, KS Biomedix & biotechnology including Bioventix Amersham, Celltech, Chroma, Clinigen, Consort Medical & F2G ▪Peter rem
Slide 14: Environmental, Social and Governance
13 Environmental, Social and Governance ▪ Environment and Sustainability: • Objective: increase the productivity of antibody manufacturing processes to reduce the quantities of plastic and chemical disposables used at Bioventix o 2022: One process converted from plastic flasks to bioreactors in 2022
Slide 15: Significant Shareholders
14 Significant Shareholders Institution Shares % (1000s) Sanford DeLand 1,040 20.0 Total shares = 5,215,685 (Mar 2023) Liontrust 571 11.0 Gresham House 465 8.9 Peter Harrison 359 6.9 ▪From permissions, other Hargreaves Lansdown Stockbrokers 343 6.6 available data and TR-1 forms Danske Bank 155 2.9 r
Slide 16: Conclusions and Outlook
15 Conclusions and Outlook ▪ Sales of our vitamin D antibody and other core SMAs have been in line with expectations ▪ Troponin revenues have increased significantly ▪ Research work on Tau for Alzheimer’s disease diagnostics continues and we remain excited by the data emerging from our collaboration